entresto 49mg51mg tablets
novartis pharmaceuticals uk ltd - valsartan; sacubitril - tablet - 51mg ; 49mg
entresto 24mg26mg tablets
novartis pharmaceuticals uk ltd - sacubitril; valsartan - tablet - 24mg ; 26mg
entresto 97mg103mg tablets
novartis pharmaceuticals uk ltd - sacubitril; valsartan - tablet - 97mg ; 103mg
exforge hct 5mg/160mg/12.5mg tablets film-coated
novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 5mg+ 160mg+ 12,5mg
exforge hct 10mg/160mg/12.5mg tablets film-coated
novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 10mg+ 160mg+ 12,5mg
exforge hct 5mg/160mg/25mg tablets film-coated
novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 5mg+ 160mg+ 25mg
exforge hct 10mg/160mg/25mg tablets film-coated
novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 10mg+ 160mg+ 25mg
entresto 100 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy.
entresto 100 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
entresto 100 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy